Ironwood Pharmaceuticals Upgraded to “Outperform” by Cowen and Company (IRWD)
Ironwood Pharmaceuticals (NASDAQ:IRWD) was upgraded by analysts at Cowen and Company from a “market perform” rating to an “outperform” rating in a research report issued to clients and investors on Thursday, TheFlyOnTheWall.com reports. The firm currently has a $14.00 price objective on the stock. Cowen and Company’s price target would suggest a potential upside of 39.58% from the stock’s previous close.
A number of other firms have also recently commented on IRWD. Analysts at Wedbush cut their price target on shares of Ironwood Pharmaceuticals from $12.00 to $10.00 in a research note to investors on Wednesday. They now have a “neutral” rating on the stock. Separately, analysts at Cantor Fitzgerald cut their price target on shares of Ironwood Pharmaceuticals from $10.00 to $9.00 in a research note to investors on Wednesday. They now have a “hold” rating on the stock. Finally, analysts at Zacks reiterated an “outperform” rating on shares of Ironwood Pharmaceuticals in a research note to investors on Wednesday, October 16th. They now have a $13.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the company’s stock. Ironwood Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $13.59.
Ironwood Pharmaceuticals (NASDAQ:IRWD) traded down 1.47% on Thursday, hitting $10.03. The stock had a trading volume of 1,349,157 shares. Ironwood Pharmaceuticals has a one year low of $9.83 and a one year high of $19.67. The stock’s 50-day moving average is $11.89 and its 200-day moving average is $13.81. The company’s market cap is $1.138 billion.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Tuesday, October 22nd. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.06. The company had revenue of $4.90 million for the quarter, compared to the consensus estimate of $6.54 million. During the same quarter in the previous year, the company posted $0.42 earnings per share. The company’s revenue for the quarter was down 94.9% on a year-over-year basis. On average, analysts predict that Ironwood Pharmaceuticals will post $-2.44 earnings per share for the current fiscal year.
Ironwood Pharmaceuticals, Inc is a pharmaceutical company, which discovers, develops and intends to commercialize differentiated medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.